SLPI and type 2 diabetes mellitus: The results showed that in both AP and T2DM, ARHGEF9 was significantly downregulated in pathways related to DNA regulation, fatty acid metabolism, cytokine–cytokine receptor interactions, and chemokine signaling, whereas SLPI was significantly enriched in pathways related to the regulation of protein response and localization, glyoxylate and dicarboxylate metabolism, and cytokine–cytokine receptor interactions.